Skip to main content

CCTG Connection



Published:
Category: News

Everyone at CCTG would like to congratulate Dr Frances Shepherd who was recently awarded the Lifetime Contribution Prize from the Canadian Cancer Society. She is an international leader in clinical and translational lung cancer research whose work has transformed the standard of care for patients in Canada and around the world.

Read More

Published:
Category: Publications
LY17: Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma publication
 
Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Rodrigo JA, Song K, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
Read More

Published:
Category: Trials
The CRC10 colon cancer trial looks at ctDNA to identify the right treatment after surgery.

Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood (circulating tumour DNA – ctDNA) as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour.

Read More

Published:
Category: Trials
Closed to Accrual: MA41
The MA41 study: De-Escalation of adjuvant ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO) has closed to accrual. The sponsors Breast International Group and Institut Jules Bordet have decided to close the recruitment of this trial.
 
For more information please visit the MA41 members trial page.
Read More



Published:
Category: Group updates
Patient Representatives Committee updates
Updates from the Patient Representatives Committee; Patient engagement in cancer research in Canada community of practice, patient engagement resources now available and update on membership. Read More

Published:
Category: Group updates
CCTG EDIIA Working Groups still accepting new members!

CCTG is still accepting members for our Equity, Diversity, Inclusivity, Indigenization, Accessibility (EDIIA) Working Groups as we strive to create a more equitable, diverse, inclusive, accessible, and culturally safe community for our network and for our patient participants. 

Read More

Published:
Category: Publications
Publication: MA32 Secondary Analysis and a Colorectal correlative study
MA32 secondary analysis: Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
 
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR.
Read More

Published:
Category: Trials
CCTG HD12 a hematology trial investigating targeted therapy for early-stage Hodgkin lymphoma opens in Canada

The CCTG HD12 trial is the second study in the RADAR international trial and has recently opened in Canada. Researchers will compare the usual treatment for Hodgkin lymphoma, with a new treatment that takes the standard combination drug treatment replacing one of the drugs with brentuximab vedotin that may be more effective and cause fewer side effects for patients.

Read More